Spending too much time and
capital on the trial-and-error approach to Drug
Discovery?
On average, only
one in a thousand drug candidates make it to
human clinical trials. The cost and time
associated with the traditional method of drug
development is expensive and quite slow (7 to 15 years and
almost $1 Billion). However, Aptagen's
technology
significantly
reduces the
unpredictability, cost, and time for drug
discovery and development.
Over a century ago, Paul Ehrlich described the
ideal drug, famously known as a ‘magic
bullet,’ in which it specifically targets
the disease site and would not harm healthy
tissue. However, finding these magic bullets
with drug-like properties involves a trial and
error approach and is extremely slow.
Aptagen has developed the concept of a
‘replicating magic bullet’ called an aptabodyTM.
The aptabodyTM technology has a
shorter development time compared to traditional
methods of drug development, and can be used to
increase the specificity and improve delivery of
existing drug compounds resulting in the next
generation of pharmaceuticals with improved
pharmacodynamics and pharmacokinetics.
